Valeant Announces New Leadership Team

Valeant Dermatology has introduced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The senior team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn, vice president of professional and specialty development; Ed Shupenus, executive director of marketing operations; and Steve Kreider, executive director of sales and marketing for SILIQ (brodalumab) injection for subcutaneous use.

McMyne most recently served as vice president of operations for Merz North America. Prior to joining Merz, he held various commercial roles at Medicis Pharmaceuticals, including associate director of sales for dermatology.

Williams has diverse experience in commercial healthcare that includes medical devices, pharmaceuticals, R&D, and manufacturing. Prior to this new role, she was senior marketing director for Merz North America.

Kreider has extensive experience in marketing. He joined Merz as director of business development, culminating with the commercial integration of Ulthera. Prior to Merz, he held sales and marketing leadership roles at Medicis, and later Valeant after its 2012 acquisition of the company.

Hahn joined Valeant in 2011 as director, professional relations for Valeant Dermatology. Previously, he worked at Ortho Dermatologics, a division of Johnson & Johnson.

Shupenus came to Valeant from Ortho Dermatologics, where he was the global group product director overseeing marketing for a dermatology portfolio.

“This team has a proven track record of results, execution and strategic agility within specialty pharmaceuticals and more specifically, the specialty of dermatology,” said Humphries. “Our team will be very visible and engaged with our customers as the first step to rebuilding their trust in the company, discussing our company’s deep dermatology pipeline, and increased spending in research and development. The Valeant Dermatology leadership team is committed to securing the company’s future in the dermatology space.”